Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy
<b>Background:</b> Food allergy (FA) poses a major global health issue due to the increasing prevalence and lack of effective prevention strategies. Allergen-specific immunotherapy (AIT) has emerged as a disease-modifying therapy for FA. However, due to long-term treatment duration and u...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-04-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/5/448 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850256156472115200 |
|---|---|
| author | Xianyu Shao Lijing Liu Changzhen Weng Kun Guo Zhutao Lu Lulu Huang Zhenhua Di Yixuan Guo Guorong Di Renmei Qiao Jingyi Wang Yong Yang Shiyu Sun Shentian Zhuang Ang Lin |
| author_facet | Xianyu Shao Lijing Liu Changzhen Weng Kun Guo Zhutao Lu Lulu Huang Zhenhua Di Yixuan Guo Guorong Di Renmei Qiao Jingyi Wang Yong Yang Shiyu Sun Shentian Zhuang Ang Lin |
| author_sort | Xianyu Shao |
| collection | DOAJ |
| description | <b>Background:</b> Food allergy (FA) poses a major global health issue due to the increasing prevalence and lack of effective prevention strategies. Allergen-specific immunotherapy (AIT) has emerged as a disease-modifying therapy for FA. However, due to long-term treatment duration and unexpected adverse reactions, only a minority of patients benefit from AIT. Therefore, effective prophylactic interventions are urgently needed for FA patients. <b>Methods:</b> In this proof-of-concept study, using a well-established mRNA platform, we developed mRNA vaccine candidates encoding for the major egg white allergen Gal d2 and comprehensively evaluated their prophylactic efficacy against anaphylaxis in a Gal d2-induced allergic mouse model. <b>Results:</b> Two vaccine formulations, Gal d2 mRNA vaccine and Gal d2-IL-10 mRNA vaccine, both demonstrated potent ability in inducing allergen-specific IgG and Th1-type T cells. Importantly, the two vaccine formulations showed promise in preventing the onset of allergic disease, which is indicated by prevention of body temperature decline during anaphylaxis. <b>Conclusions:</b> We provided preliminary proof-of-concept evidence showing that the mRNA platform is unique and holds promise for the development of anti-allergy vaccines. This is largely attributed to the capacities of mRNA vaccines in eliciting an allergen-blocking antibody, shifting Th2 towards Th1 immunity, as well as in generating peripheral tolerance. However, further investigations are required to better understand the mode of action. |
| format | Article |
| id | doaj-art-cf93be042c9742bb91e5ad7cbd187b48 |
| institution | OA Journals |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-04-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-cf93be042c9742bb91e5ad7cbd187b482025-08-20T01:56:42ZengMDPI AGVaccines2076-393X2025-04-0113544810.3390/vaccines13050448Leveraging an mRNA Platform for the Development of Vaccines Against Egg AllergyXianyu Shao0Lijing Liu1Changzhen Weng2Kun Guo3Zhutao Lu4Lulu Huang5Zhenhua Di6Yixuan Guo7Guorong Di8Renmei Qiao9Jingyi Wang10Yong Yang11Shiyu Sun12Shentian Zhuang13Ang Lin14Center for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, ChinaCenter for Infectious Medicine and Vaccine Research, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China<b>Background:</b> Food allergy (FA) poses a major global health issue due to the increasing prevalence and lack of effective prevention strategies. Allergen-specific immunotherapy (AIT) has emerged as a disease-modifying therapy for FA. However, due to long-term treatment duration and unexpected adverse reactions, only a minority of patients benefit from AIT. Therefore, effective prophylactic interventions are urgently needed for FA patients. <b>Methods:</b> In this proof-of-concept study, using a well-established mRNA platform, we developed mRNA vaccine candidates encoding for the major egg white allergen Gal d2 and comprehensively evaluated their prophylactic efficacy against anaphylaxis in a Gal d2-induced allergic mouse model. <b>Results:</b> Two vaccine formulations, Gal d2 mRNA vaccine and Gal d2-IL-10 mRNA vaccine, both demonstrated potent ability in inducing allergen-specific IgG and Th1-type T cells. Importantly, the two vaccine formulations showed promise in preventing the onset of allergic disease, which is indicated by prevention of body temperature decline during anaphylaxis. <b>Conclusions:</b> We provided preliminary proof-of-concept evidence showing that the mRNA platform is unique and holds promise for the development of anti-allergy vaccines. This is largely attributed to the capacities of mRNA vaccines in eliciting an allergen-blocking antibody, shifting Th2 towards Th1 immunity, as well as in generating peripheral tolerance. However, further investigations are required to better understand the mode of action.https://www.mdpi.com/2076-393X/13/5/448mRNA technologyfood allergyegg allergyanaphylaxispreventive effect |
| spellingShingle | Xianyu Shao Lijing Liu Changzhen Weng Kun Guo Zhutao Lu Lulu Huang Zhenhua Di Yixuan Guo Guorong Di Renmei Qiao Jingyi Wang Yong Yang Shiyu Sun Shentian Zhuang Ang Lin Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy Vaccines mRNA technology food allergy egg allergy anaphylaxis preventive effect |
| title | Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy |
| title_full | Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy |
| title_fullStr | Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy |
| title_full_unstemmed | Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy |
| title_short | Leveraging an mRNA Platform for the Development of Vaccines Against Egg Allergy |
| title_sort | leveraging an mrna platform for the development of vaccines against egg allergy |
| topic | mRNA technology food allergy egg allergy anaphylaxis preventive effect |
| url | https://www.mdpi.com/2076-393X/13/5/448 |
| work_keys_str_mv | AT xianyushao leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT lijingliu leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT changzhenweng leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT kunguo leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT zhutaolu leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT luluhuang leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT zhenhuadi leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT yixuanguo leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT guorongdi leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT renmeiqiao leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT jingyiwang leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT yongyang leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT shiyusun leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT shentianzhuang leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy AT anglin leveraginganmrnaplatformforthedevelopmentofvaccinesagainsteggallergy |